日本神经生物标记市场按类型、应用、最终用途和地区划分，2026-2034年

2025年，日本神经生物标记市场规模达6.239亿美元。展望未来，IMARC集团预测，到2034年，该市场规模将达到9.868亿美元，2026年至2034年的复合年增长率为5.23%。有效治疗方案的日益普及和对更快药物研发的需求不断增长是推动市场成长的主要因素。

存在于血液或脑脊髓液中的神经生物标记可以识别脑部疾病并追踪其进展。这些生物标记主要来自基因突变、代谢物水平、脑部影像、蛋白质表现变化以及转译后修饰。神经生物标记在药物研发过程中发挥着重要的临床应用作用，因为它们能够识别实验药物的生物学反应，并有助于发现新的治疗性介入标靶。科学家目前正在分析这些生物标记的浓度，以实现非侵入性检测、早期诊断和个人化治疗。

日本神经生物标记市场的发展趋势：

由于中风、运动神经元疾病（MND）、阿兹海默症（AD）、帕金森氏症（PD）和亨廷顿舞蹈症（HD）等神经系统疾病的盛行率不断上升，日本的神经生物标记市场正经历显着增长。神经系统疾病的激增催生了对加速药物研发的迫切需求，从而推动了市场成长。此外，生物标记在评估新药和治疗方法的有效性方面发挥关键作用，极大地促进了这一增长势头。微创手术和个人化医疗实践的广泛应用也是该地区市场扩张的关键驱动因素。此外，由于各种神经系统疾病通常具有通用特征，因此对能够区分特定疾病及其亚型的多种生物标记的需求日益增长，进一步刺激了市场需求。同时，质谱和成像诊断技术的进步使得快速评估大脑中多种生化标记和结构变化成为可能，从而提高了诊断能力。预计未来几年，随着数位生物标记的采用和临床试验数量的不断增加，这将进一步推动日本神经生物标记市场的成长。

本报告解答的关键问题

• 日本神经生物标记市场的趋势和未来前景如何？
• 新冠疫情对日本神经生物标记市场产生了哪些影响？
• 日本神经生物标记市场按类型是如何分類的？
• 日本神经生物标记市场按应用领域是如何分類的？
• 日本神经生物标记市场依最终用途分類的情况如何？
• 日本神经生物标记市场价值链的不同阶段有哪些？
• 日本神经生物标记市场的主要驱动因素和挑战是什么？
• 日本神经生物标记市场的结构是怎么样的？主要企业有哪些？
• 日本神经生物标记市场竞争有多激烈？

目录

第一章：序言

第二章：调查范围与调查方法

• 调查目标
• 相关利益者
• 数据来源
• 市场估值
• 调查方法

第三章执行摘要

第四章 日本神经生物标记市场：简介

• 概述
• 市场动态
• 产业趋势
• 竞争资讯

第五章 日本神经生物标记市场概述

• 过去和当前的市场趋势（2020-2025）
• 市场预测（2026-2034）

第六章：日本神经生物标记市场（按类型划分）

• 基因生物标誌物
• 蛋白质体学生物标誌物
• 代谢体学物标誌物
• 影像生物标记
• 其他的

第七章：日本神经生物标记市场：按应用细分

• 阿兹海默症
• 帕金森氏症
• 多发性硬化症
• 自闭症频谱障碍
• 其他的

第八章：日本神经生物标记市场（依最终用途划分）

• 医院检查室
• 临床诊断中心
• 研究所
• 其他的

第九章：日本神经生物标记市场：按地区划分

• 关东地区
• 关西、近畿地区
• 中部地区
• 九州和冲绳地区
• 东北部地区
• 中国地区
• 北海道地区
• 四国地区

第十章：日本神经生物标记市场：竞争格局

• 概述
• 市场结构
• 市场公司定位
• 关键成功策略
• 竞争对手仪錶板
• 企业估值象限

第十一章主要企业概况

第十二章：日本神经生物标记市场：产业分析

• 驱动因素、限制因素和机会
• 波特五力分析
• 价值链分析

第十三章附录

Japan neurological biomarkers market size reached USD 623.9 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 986.8 Million by 2034, exhibiting a growth rate (CAGR) of 5.23% during 2026-2034. The inflating adoption of effective treatment plans and the escalating demand for faster drug development are primarily driving the market growth.

Access the full market insights report Request Sample

Neurological biomarkers , found in either the blood or cerebral spinal fluid (CSF), serve to facilitate the identification of brain disorders and track the advancement of diseases. These biomarkers primarily originate from genetic mutations, levels of metabolites, brain imaging, and alterations in the expression of proteins or modifications after translation. With their ability to identify biological reactions to experimental medications and assist in the exploration of novel targets for therapeutic intervention, neurological biomarkers play a significant role in clinical applications throughout the drug development process. Currently, scientists analyze the concentrations of these biomarkers to enable non-invasive testing, early diagnosis, and the customization of treatments.

JAPAN NEUROLOGICAL BIOMARKERS MARKET TRENDS:

The Japan neurological biomarkers market is witnessing a notable upsurge owing to the escalating prevalence of neurological disorders, including conditions like stroke, motor neuron disease (MND), Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD). This surge in neurological disorders has generated a pressing demand for accelerated drug development, thereby driving the market growth. Besides this, biomarkers play a pivotal role in measuring the effectiveness of novel medications and therapeutic approaches, contributing significantly to this momentum. Additionally, the growing acceptance of minimally invasive procedures and personalized medicine practices is serving as another crucial catalyst for market expansion in the region. Furthermore, as various neurological disorders often exhibit shared characteristics, there is an increasing requirement for multiple biomarkers to differentiate between specific diseases and their subtypes, further fueling market demand. Apart from this, advancements in mass spectrometry and imaging techniques have facilitated the rapid evaluation of numerous biochemical markers and structural changes within the brain, enabling enhanced diagnostic capabilities. This, coupled with the introduction of digital biomarkers and the continual rise in the number of clinical trials, is expected to further propel the growth of the Japan neurological biomarkers market in the forthcoming years.

JAPAN NEUROLOGICAL BIOMARKERS MARKET SEGMENTATION:

Type Insights:

• To get detailed segment analysis of this market Request Sample
• Genomic Biomarkers
• Proteomic Biomarkers
• Metabolomic Biomarkers
• Imaging Biomarkers
• Others
• Genomic Biomarkers
• Proteomic Biomarkers
• Metabolomic Biomarkers
• Imaging Biomarkers
• Others

Application Insights:

• Alzheimer's Disease
• Parkinson's Disease
• Multiple Sclerosis
• Autism Spectrum Disorders
• Others
• Alzheimer's Disease
• Parkinson's Disease
• Multiple Sclerosis
• Autism Spectrum Disorders
• Others

End Use Insights:

• Hospital Laboratories
• Clinical Diagnostic Centers
• Research Organizations
• Others
• Hospital Laboratories
• Clinical Diagnostic Centers
• Research Organizations
• Others

Regional Insights:

• To get detailed regional analysis of this market Request Sample
• Kanto Region
• Kansai/Kinki Region
• Central/ Chubu Region
• Kyushu-Okinawa Region
• Tohoku Region
• Chugoku Region
• Hokkaido Region
• Shikoku Region
• Kanto Region
• Kansai/Kinki Region
• Central/ Chubu Region
• Kyushu-Okinawa Region
• Tohoku Region
• Chugoku Region
• Hokkaido Region
• Shikoku Region
• The report has also provided a comprehensive analysis of all the major regional markets, which include Kanto Region, Kansai/Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, and Shikoku Region.

COMPETITIVE LANDSCAPE:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

• KEY QUESTIONS ANSWERED IN THIS REPORT
• How has the Japan neurological biomarkers market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the Japan neurological biomarkers market?
• What is the breakup of the Japan neurological biomarkers market on the basis of type?
• What is the breakup of the Japan neurological biomarkers market on the basis of application?
• What is the breakup of the Japan neurological biomarkers market on the basis of end use?
• What are the various stages in the value chain of the Japan neurological biomarkers market?
• What are the key driving factors and challenges in the Japan neurological biomarkers?
• What is the structure of the Japan neurological biomarkers market and who are the key players?
• What is the degree of competition in the Japan neurological biomarkers market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Neurological Biomarkers Market - Introduction

• 4.1 Overview
• 4.2 Market Dynamics
• 4.3 Industry Trends
• 4.4 Competitive Intelligence

5 Japan Neurological Biomarkers Market Landscape

• 5.1 Historical and Current Market Trends (2020-2025)
• 5.2 Market Forecast (2026-2034)

6 Japan Neurological Biomarkers Market - Breakup by Type

• 6.1 Genomic Biomarkers
  • 6.1.1 Overview
  • 6.1.2 Historical and Current Market Trends (2020-2025)
  • 6.1.3 Market Forecast (2026-2034)
• 6.2 Proteomic Biomarkers
  • 6.2.1 Overview
  • 6.2.2 Historical and Current Market Trends (2020-2025)
  • 6.2.3 Market Forecast (2026-2034)
• 6.3 Metabolomic Biomarkers
  • 6.3.1 Overview
  • 6.3.2 Historical and Current Market Trends (2020-2025)
  • 6.3.3 Market Forecast (2026-2034)
• 6.4 Imaging Biomarkers
  • 6.4.1 Overview
  • 6.4.2 Historical and Current Market Trends (2020-2025)
  • 6.4.3 Market Forecast (2026-2034)
• 6.5 Others
  • 6.5.1 Historical and Current Market Trends (2020-2025)
  • 6.5.2 Market Forecast (2026-2034)

7 Japan Neurological Biomarkers Market - Breakup by Application

• 7.1 Alzheimer's Disease
  • 7.1.1 Overview
  • 7.1.2 Historical and Current Market Trends (2020-2025)
  • 7.1.3 Market Forecast (2026-2034)
• 7.2 Parkinson's Disease
  • 7.2.1 Overview
  • 7.2.2 Historical and Current Market Trends (2020-2025)
  • 7.2.3 Market Forecast (2026-2034)
• 7.3 Multiple Sclerosis
  • 7.3.1 Overview
  • 7.3.2 Historical and Current Market Trends (2020-2025)
  • 7.3.3 Market Forecast (2026-2034)
• 7.4 Autism Spectrum Disorders
  • 7.4.1 Overview
  • 7.4.2 Historical and Current Market Trends (2020-2025)
  • 7.4.3 Market Forecast (2026-2034)
• 7.5 Others
  • 7.5.1 Historical and Current Market Trends (2020-2025)
  • 7.5.2 Market Forecast (2026-2034)

8 Japan Neurological Biomarkers Market - Breakup by End Use

• 8.1 Hospital Laboratories
  • 8.1.1 Overview
  • 8.1.2 Historical and Current Market Trends (2020-2025)
  • 8.1.3 Market Forecast (2026-2034)
• 8.2 Clinical Diagnostic Centers
  • 8.2.1 Overview
  • 8.2.2 Historical and Current Market Trends (2020-2025)
  • 8.2.3 Market Forecast (2026-2034)
• 8.3 Research Organizations
  • 8.3.1 Overview
  • 8.3.2 Historical and Current Market Trends (2020-2025)
  • 8.3.3 Market Forecast (2026-2034)
• 8.4 Others
  • 8.4.1 Historical and Current Market Trends (2020-2025)
  • 8.4.2 Market Forecast (2026-2034)

9 Japan Neurological Biomarkers Market - Breakup by Region

• 9.1 Kanto Region
  • 9.1.1 Overview
  • 9.1.2 Historical and Current Market Trends (2020-2025)
  • 9.1.3 Market Breakup by Type
  • 9.1.4 Market Breakup by Application
  • 9.1.5 Market Breakup by End Use
  • 9.1.6 Key Players
  • 9.1.7 Market Forecast (2026-2034)
• 9.2 Kansai/Kinki Region
  • 9.2.1 Overview
  • 9.2.2 Historical and Current Market Trends (2020-2025)
  • 9.2.3 Market Breakup by Type
  • 9.2.4 Market Breakup by Application
  • 9.2.5 Market Breakup by End Use
  • 9.2.6 Key Players
  • 9.2.7 Market Forecast (2026-2034)
• 9.3 Central/ Chubu Region
  • 9.3.1 Overview
  • 9.3.2 Historical and Current Market Trends (2020-2025)
  • 9.3.3 Market Breakup by Type
  • 9.3.4 Market Breakup by Application
  • 9.3.5 Market Breakup by End Use
  • 9.3.6 Key Players
  • 9.3.7 Market Forecast (2026-2034)
• 9.4 Kyushu-Okinawa Region
  • 9.4.1 Overview
  • 9.4.2 Historical and Current Market Trends (2020-2025)
  • 9.4.3 Market Breakup by Type
  • 9.4.4 Market Breakup by Application
  • 9.4.5 Market Breakup by End Use
  • 9.4.6 Key Players
  • 9.4.7 Market Forecast (2026-2034)
• 9.5 Tohoku Region
  • 9.5.1 Overview
  • 9.5.2 Historical and Current Market Trends (2020-2025)
  • 9.5.3 Market Breakup by Type
  • 9.5.4 Market Breakup by Application
  • 9.5.5 Market Breakup by End Use
  • 9.5.6 Key Players
  • 9.5.7 Market Forecast (2026-2034)
• 9.6 Chugoku Region
  • 9.6.1 Overview
  • 9.6.2 Historical and Current Market Trends (2020-2025)
  • 9.6.3 Market Breakup by Type
  • 9.6.4 Market Breakup by Application
  • 9.6.5 Market Breakup by End Use
  • 9.6.6 Key Players
  • 9.6.7 Market Forecast (2026-2034)
• 9.7 Hokkaido Region
  • 9.7.1 Overview
  • 9.7.2 Historical and Current Market Trends (2020-2025)
  • 9.7.3 Market Breakup by Type
  • 9.7.4 Market Breakup by Application
  • 9.7.5 Market Breakup by End Use
  • 9.7.6 Key Players
  • 9.7.7 Market Forecast (2026-2034)
• 9.8 Shikoku Region
  • 9.8.1 Overview
  • 9.8.2 Historical and Current Market Trends (2020-2025)
  • 9.8.3 Market Breakup by Type
  • 9.8.4 Market Breakup by Application
  • 9.8.5 Market Breakup by End Use
  • 9.8.6 Key Players
  • 9.8.7 Market Forecast (2026-2034)

10 Japan Neurological Biomarkers Market - Competitive Landscape

• 10.1 Overview
• 10.2 Market Structure
• 10.3 Market Player Positioning
• 10.4 Top Winning Strategies
• 10.5 Competitive Dashboard
• 10.6 Company Evaluation Quadrant

11 Profiles of Key Players

• 11.1 Company A
  • 11.1.1 Business Overview
  • 11.1.2 Services Offered
  • 11.1.3 Business Strategies
  • 11.1.4 SWOT Analysis
  • 11.1.5 Major News and Events
• 11.2 Company B
  • 11.2.1 Business Overview
  • 11.2.2 Services Offered
  • 11.2.3 Business Strategies
  • 11.2.4 SWOT Analysis
  • 11.2.5 Major News and Events
• 11.3 Company C
  • 11.3.1 Business Overview
  • 11.3.2 Services Offered
  • 11.3.3 Business Strategies
  • 11.3.4 SWOT Analysis
  • 11.3.5 Major News and Events
• 11.4 Company D
  • 11.4.1 Business Overview
  • 11.4.2 Services Offered
  • 11.4.3 Business Strategies
  • 11.4.4 SWOT Analysis
  • 11.4.5 Major News and Events
• 11.5 Company E
  • 11.5.1 Business Overview
  • 11.5.2 Services Offered
  • 11.5.3 Business Strategies
  • 11.5.4 SWOT Analysis
  • 11.5.5 Major News and Events

12 Japan Neurological Biomarkers Market - Industry Analysis

• 12.1 Drivers, Restraints, and Opportunities
  • 12.1.1 Overview
  • 12.1.2 Drivers
  • 12.1.3 Restraints
  • 12.1.4 Opportunities
• 12.2 Porters Five Forces Analysis
  • 12.2.1 Overview
  • 12.2.2 Bargaining Power of Buyers
  • 12.2.3 Bargaining Power of Suppliers
  • 12.2.4 Degree of Competition
  • 12.2.5 Threat of New Entrants
  • 12.2.6 Threat of Substitutes
• 12.3 Value Chain Analysis

13 Appendix